PURPOSE OF REVIEW: Effective treatment exists for tuberculosis (TB) and for HIV, but treating both diseases simultaneously presents several challenges. This review assesses the evidence for the timing of antiretroviral therapy (ART) initiation in patients coinfected with TB. RECENT FINDINGS: Published evidence clearly demonstrates that TB-HIV integration is essential for improved survival, but the question of when to start ART during TB treatment is more complex. Five randomized controlled trials assessed this question: four trials showed no difference in the incidence rates of AIDS or death between TB patients initiating ART within 2 months compared to later during TB therapy, while one trial showed a significant survival gain with ART initiation within 2 weeks of TB therapy start. All five studies found improved AIDS-free survival with earlier ART initiation in TB patients with low CD4 T-cell counts, except among patients with TB meningitis. The survival benefit was, however, accompanied by increased immune reconstitution inflammatory syndrome events. SUMMARY: The trial data support the World Health Organization recommendations on when to start ART in TB-HIV coinfected patients including earlier ART initiation in severely immune-compromised patients. However, several challenges remain in integrating TB and HIV treatment in public healthcare services. Additional research on timing of ART is needed for patients with drug-resistant and extrapulmonary TB, notably TB meningitis.
PURPOSE OF REVIEW: Effective treatment exists for tuberculosis (TB) and for HIV, but treating both diseases simultaneously presents several challenges. This review assesses the evidence for the timing of antiretroviral therapy (ART) initiation in patients coinfected with TB. RECENT FINDINGS: Published evidence clearly demonstrates that TB-HIV integration is essential for improved survival, but the question of when to start ART during TB treatment is more complex. Five randomized controlled trials assessed this question: four trials showed no difference in the incidence rates of AIDS or death between TB patients initiating ART within 2 months compared to later during TB therapy, while one trial showed a significant survival gain with ART initiation within 2 weeks of TB therapy start. All five studies found improved AIDS-free survival with earlier ART initiation in TB patients with low CD4 T-cell counts, except among patients with TB meningitis. The survival benefit was, however, accompanied by increased immune reconstitution inflammatory syndrome events. SUMMARY: The trial data support the World Health Organization recommendations on when to start ART in TB-HIV coinfectedpatients including earlier ART initiation in severely immune-compromised patients. However, several challenges remain in integrating TB and HIV treatment in public healthcare services. Additional research on timing of ART is needed for patients with drug-resistant and extrapulmonary TB, notably TB meningitis.
Authors: Diane V Havlir; Michelle A Kendall; Prudence Ive; Johnstone Kumwenda; Susan Swindells; Sarojini S Qasba; Anne F Luetkemeyer; Evelyn Hogg; James F Rooney; Xingye Wu; Mina C Hosseinipour; Umesh Lalloo; Valdilea G Veloso; Fatuma F Some; N Kumarasamy; Nesri Padayatchi; Breno R Santos; Stewart Reid; James Hakim; Lerato Mohapi; Peter Mugyenyi; Jorge Sanchez; Javier R Lama; Jean W Pape; Alejandro Sanchez; Aida Asmelash; Evans Moko; Fred Sawe; Janet Andersen; Ian Sanne Journal: N Engl J Med Date: 2011-10-20 Impact factor: 91.245
Authors: Molly F Franke; James M Robins; Jules Mugabo; Felix Kaigamba; Lauren E Cain; Julia G Fleming; Megan B Murray Journal: PLoS Med Date: 2011-05-03 Impact factor: 11.069
Authors: Stephen D Lawn; Lucy Campbell; Richard Kaplan; Francesca Little; Carl Morrow; Robin Wood Journal: BMC Infect Dis Date: 2011-09-30 Impact factor: 3.090
Authors: Sarah M Burnett; Stella Zawedde-Muyanja; Sabine M Hermans; Marcia R Weaver; Robert Colebunders; Yukari C Manabe Journal: J Acquir Immune Defic Syndr Date: 2018-12-15 Impact factor: 3.731
Authors: Janice J Endsley; Matthew B Huante; Kubra F Naqvi; Benjamin B Gelman; Mark A Endsley Journal: Retrovirology Date: 2021-06-16 Impact factor: 4.602
Authors: Jean Joel R Bigna; Jean Jacques N Noubiap; Ako A Agbor; Claudia S Plottel; Serge Clotaire Billong; André Patrick R Ayong; Sinata Koulla-Shiro Journal: PLoS One Date: 2015-07-27 Impact factor: 3.240
Authors: Denis Nash; Olga Tymejczyk; Tsigereda Gadisa; Sarah Gorrell Kulkarni; Susie Hoffman; Muluneh Yigzaw; Batya Elul; Robert H Remien; Maria Lahuerta; Shalo Daba; Wafaa El Sadr; Zenebe Melaku Journal: J Int AIDS Soc Date: 2016-04-22 Impact factor: 5.396